ArticlePloS one2025
The global impact of non-alcoholic fatty liver disease (including cirrhosis) in the elderly from 1990 to 2021 and future projections of disease burden.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease in the Aging Population: A Narrative Review of Pathophysiological Synergy, Diagnostic Challenges, and Tailored Management.Current gastroenterology reports · 2026Review
- The LKB1-AMPK pathway in NAFLD: molecular mechanisms and therapeutic implications.Journal of physiology and biochemistry · 2026Review
- A Retrospective Analysis of Hepatic Disease Burden and Progression in a Hospital-Based Romanian Cohort Using Integrated Cross-Sectional and Longitudinal Data (2019-2023).Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by hepatic steatosis and inflammation in individuals with no significant alcohol consumption history. Predominantly affecting middle-aged and elderly populations, particularly those with obesity or metabolic syndrome, this condition represents a spectrum ranging from benign fatty accumulation to progressive liver damage. In advanced stages, NAFLD may progress to cirrhosis and hepatocellular carcinoma. This study systematically examines the global incidence patterns and epidemiological characteristics of NAFLD in older adults(>60 years), while establishing predictive models for its future disease burden.
methodsData on NAFLD in the Elderly(>60 years), from 1990 to 2021, was obtained from the Global Burden of Disease (GBD) study, encompassing 204 countries and territories. This dataset includes incidence rates of NAFLD. The Joinpoint regression model was utilized to detect turning points in the epidemiological trends of NAFLD, and decomposition analysis was performed to analyze the factors influencing these trends. To evaluate potential health disparities related to NAFLD, the Slope Index and Concentration Index were calculated. Additionally, the Norpred and Bayesian age-period-cohort (BAPC) models were employed to forecast future incidence rates of NAFLD.
resultsIn 1990, the global NAFLD incidence in the elderly was 2819125(3972309 ± 1807520), with an ASIR of 568.46(803.33 ± 364.10). The global NAFLD prevalence in the elderly was 132549345(166820867 ± 102941502), with an ASPR of 27284.94(34321.92 ± 21200.69). The global NAFLD deaths in the elderly were 27864(45975 ± 15898), with an age-standardized death rate of 6.20(10.18 ± 3.55). The global NAFLD DALYs in the elderly were 559945(931920 ± 319045), with an age-standardized DALYs rate of 116.78(193.49 ± 66.73). In 2021, the global NAFLD incidence in the elderly was 7,012,128 (9,896,736 ± 4,480,162), with an ASIR of 636.90 (900.15 ± 406.76). The global NAFLD prevalence in the elderly was 366,363,498 (454,385,769 ± 287,891,088), with an ASPR of 33,576.22 (41,647.44 ± 26,372.13). The global NAFLD deaths in the elderly were 63,313 (99,891 ± 37,267), with an age-standardized death rate of 5.95 (9.39 ± 3.50). The global NAFLD DALYs in the elderly were 1,238,927 (1,973,042 ± 729,228), with an age-standardized DALYs rate of 113.95 (181.50 ± 66.91). From 1990 to 2021, the AAPC of ASIR for NAFLD in the elderly globally was 0.37(0.36 to 0.38), with a p-value < 0.05. The AAPC of ASPR for NAFLD in the elderly globally was 0.67(0.65 to 0.68), with a p-value < 0.05. The AAPC of age-standardized deaths rate for NAFLD in the elderly globally was -0.13(-0.16 to -0.1), with a p-value < 0.05. The AAPC of age-standardized DALYs rate for NAFLD in the elderly globally was -0.05(-0.07 to -0.02), with a p-value < 0.05. The decomposition analysis results indicate that population growth is the primary driver of increased disease burden in older NAFLD patients. It is expected that in the future, the disease burden of NAFLD in elderly people worldwide will continue to rise.
conclusionsOver the past three decades, the annual age-standardized incidence rate and total number of cases of NAFLD, including cirrhosis, have increased among the elderly population, irrespective of gender. This upward trend is consistent across all SDI regions. Furthermore, future projections indicate that both the annual age-standardized incidence rate and the case numbers of NAFLD, including cirrhosis, in the elderly are likely to continue rising.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.